Alberto Jacobo Cunquero-Tomás

Alberto Jacobo Cunquero-Tomás

Auto-generated profile, based on publicly available information

Alberto Jacobo Cunquero-Tomás

Medical Oncology Consorcio Hospital General Universitario de Valencia Valencia Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
STSusana Torres-Martínez
Susana Torres-Martínez
ÁGÁlvaro González
Álvaro González
ATAlberto Jacobo Cunquero Tomas
Alberto Jacobo Cunquero Tomas
SCSilvia Calabuig-Fariñas
Silvia Calabuig-Fariñas
MGMacarena Ferrero Gimeno
Macarena Ferrero Gimeno
CCCarlos Camps
Carlos Camps
Introduction: Among non-small cell lung cancer (NSCLC) patients, there is one molecularly defined subgroup harboring activating mutations in the epidermal growth factor receptor gene (EGFR), which results in constitutive activation of its intrinsic kinase activity. Consistent data have demonstrated that these patients have a better outcome when treated with specific tyrosine-kinase inhibitors (EGFR-TKIs). Therefore, analysis of EGFR mutational status for treatment guidance is mandatory in this context. Areas covered: Herein we review the clinical development and technical features of cobas® EGFR Mutation Test v2 as a companion diagnostic test (CDx) for therapy with EGFR-TKIs, such as gefitinib, in advanced NSCLC. We also discuss the pros and cons of the current version of the CDx and its performance in both tissue and plasma samples. Expert opinion: The RT-PCR based cobas® EGFR Mutation Test v2 is a reliable and rapid solution for EGFR mutational status assessment at the time of diagnosis in advanced NSCLC that allows eligibility of patients for EGFR-TKI treatment. This test determines EGFR mutations with acceptable sensitivity in tissue or plasma samples. Pre-analytical considerations like tumor cell content, tumor burden or location of metastasis should be considered to better interpret results in the clinical contexture.

14 August 2020 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
RHRicardo Hitt
Ricardo Hitt
LIL. Iglesias
L. Iglesias
ALAntonio López-Pousa
Antonio López-Pousa
ABA. Berrocal-Jaime
A. Berrocal-Jaime
JGJ. J. Grau
J. J. Grau
T(the Spanish Head and Neck Cancer Cooperative Group (TTCC)
the Spanish Head and Neck Cancer Cooperative Group (TTCC)

11 April 2025 in ESMO Open
Verified
Journal Article
Open access
IPI. Pinker
I. Pinker
CLC. Lafont
C. Lafont
GLGabor Liposits
Gabor Liposits
radu vidraradu vidra
radu vidra
ACA.J. Cunquero-Tomás
A.J. Cunquero-Tomás
SPSophie Pilleron
Sophie Pilleron
Implementation of national cancer policy is frequently shaped by medical guidelines. These guidelines often lack detail addressing the intricate care needs of vulnerable groups such as older adults, hindering the potential impact of these policies. To provide an overview of the representation of older adults in European cancer guidelines to identify areas for improvement. A scoping review was conducted using the Arksey and O’Malley framework and Levac et al. extension. The search strategy was developed for grey literature (i.e. guidelines) for the five most prevalent primary malignancies (prostate, breast, colorectal, lung, and urinary bladder) in 29 countries (member states of the European Union, Switzerland, and the UK). Data were extracted by a national expert and at least one other reviewer. A total of 187 guideline reports from 31 jurisdictions were analysed, encompassing general cancer care and selected primary malignancies. The representation of older adults varied by cancer type and region. Dedicated guidelines for older adults were uncommon, with only a few jurisdictions, such as France and Spain, providing age-specific recommendations for certain malignancies. Although some national guidelines addressed older patients, this focus was inconsistent both across different cancers and within the guidelines of the same country. There is limited representation of geriatric oncology across European cancer guidelines. To enhance representative guideline development, there is a call for greater consideration of older adults’ unique needs. Suggestions include further guidance on the implementation of the comprehensive geriatric assessment and consequent treatment across neoadjuvant, adjuvant, and metastatic settings.

16 August 2022 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
PDF file
BMBianca Tabita Muresan
Bianca Tabita Muresan
MNMartín Núñez-Abad
Martín Núñez-Abad
AAAna Artero
Ana Artero
JRJaime Rios Rios
Jaime Rios Rios
ACAlberto Jacobo Cunquero-Tomás
Alberto Jacobo Cunquero-Tomás
Carlos Sanchez JuanCarlos Sanchez Juan
Carlos Sanchez Juan
Aim. To investigate the relation between malnutrition and nosocomial infections (NI) in hospitalized cancer patients. Methods. This observational, cross-sectional, noninterventional, descriptive study was conducted in a 500-bed university hospital in Valencia (Spain). Adult cancer patients admitted to the oncology ward were consecutively enrolled regardless of their nutritional status between November 2019 and March 2020. Patients were nutritionally assessed 24 to 48 hours after admission. Body weight, height and BMI, body composition through measurement of bioelectrical impedance analysis (BIA), and muscle strength and functionality using hand grip strength (HGS) were prospectively collected. The diagnosis of malnutrition and sarcopenia was assessed using the Global Leadership Initiative on Malnutrition (GLIM) criteria and the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, respectively. Patients were followed up during their hospital stay or outpatient oncology visits to identify possible NI. Results. A total of 107 patients were included in this study (mean age 66 years; 66.4% were men). The most frequent reason for admission was cancer treatment (19.6%), followed by infections (18.7%) and digestive tract symptoms (18.7%). Overall, 77.5% (83/107) of the patients were malnourished at admission according to the GLIM criteria, while 52.3% (56/107) were sarcopenic. Nosocomial infections (NI) were significantly more frequent in malnourished (52.1%; 25/48) and severely malnourished (42.1%; 8/19) patients, compared with well-nourished patients without malnutrition (25%; 10/40; ). The mean length of hospital stay was 13.9 days, significantly longer in patients with an NI compared to those without infections (18.6 vs. 10.8 days, ). Conclusion. This study evidenced the need to implement a routine protocol for the nutritional assessment and support of cancer patients at risk of malnutrition and sarcopenia to reduce the risk of NI during their hospital stay.

1 February 2018 in Chinese Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ACAlberto Jacobo Cunquero-Tomás
Alberto Jacobo Cunquero-Tomás
JOJose María Ortiz-Salvador
Jose María Ortiz-Salvador
VIVega Iranzo
Vega Iranzo
CCCarlos Camps
Carlos Camps
Sweet syndrome is a neutrophilic infiltration of the papillary dermis, which may be associated with the presence of unknown malignancies, either haematological or solid tumours, in 1 out of 5 cases, being considered then as a paraneoplastic syndrome. We present the case of a male with a locally advanced gastric cancer whose final diagnosis was led by the prior debut of Sweet syndrome not explained by other causes.

1 August 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
CCCarlos Camps
Carlos Camps
RLRafael López-López
Rafael López-López
AAAntonio Antón
Antonio Antón
EAEnrique Aranda
Enrique Aranda
ACAlfredo Carrato
Alfredo Carrato
VGVicente Guillem
Vicente Guillem
PURPOSE: Measuring and tracking quality of care is highly relevant in today's health care. The Quality Oncology Practice Initiative (QOPI) program is a referral for evaluating oncology practices worldwide. Excellence and Quality in Oncology Foundation, a collaboration of oncology experts from major Spanish hospitals involved in cancer treatment, reached an agreement with QOPI to include Spanish hospitals in this program. METHODS: We analyzed the results of the QOPI Core module measures from 19 Spanish hospitals over nine rounds (from fall 2015 to fall 2019). RESULTS: Of the 19 hospitals, 15 completed more than one round; none participated in all nine (two hospitals participated in eight rounds). The highest scores were for pathology report confirming malignancy, documenting a plan of care for moderate or severe pain and chemotherapy dose, and chemotherapy administered to patients with metastatic solid tumor with performance status undocumented. Measures regarding a summary of chemotherapy treatment, tobacco use cessation counseling, and assessment of patient emotional well-being were among the lowest scored measures. Six of the 15 practices that participated repeatedly achieved a better score in their last round compared with their first. Overall, scores of Spanish hospitals improved from 67.79% in fall 2015 to 68.91% in fall 2019. CONCLUSION: To our knowledge, this is the first study to evaluate QOPI scores in Spain. There was high variability in scores, with quality of care improving with repeated participation in some hospitals, but worsening in others. Excellence and Quality in Oncology Foundation will support practices to increase their participation to improve oncology care and implement strategies that address the areas for improvement.